EGFR and metastatic neoplasm: Additionally, 348 (68.5 %) received bevacizumab, 148 (29.1 %) received anti-EGFR therapy, 115 (22.6 %) received Trifluridine/Tipiracil (Lonsurf), and 12 (2.4 %) received BRAF inhibition during their treatment for metastatic disease.